| HOME >> MEDICINE >> TECHNOLOGY |
(a)
36,89610,080(430)
(c)
9,650Selling, general and administrative
162,505(32,848)
(b)
129,65772,552(12,960)
(h)
59,592Research and development
13,200(1,718)
(c)
11,48210,356(2,342)
(c)
8,014Intangible asset amortization
43,444(43,444)-5,586(5,586)-Interest expense, net
9,199(1,569)
(d)
7,6301,559(394)
(d)
1,165Loss on extinguishment of debt
---1,097(1,097)-Provision for income tax expense
24,966(6,160)
(e)
18,806---Income from continuing operations
94,943101,505196,44887,51121,955109,466Income (loss) from discontinued operations
(6,908)11,185
(f)
4,277---Diluted income (loss) per share:Income from continuing operations
$ 1.59$ 3.28$ 1.88$ 2.35Income (loss) from discontinued operations
(0.12)0.07--Total
1.473.351.882.35(a)
Purchase accounting inventory fair value step-up of $14,676, share-based compensation expense of $999 and restructuring expense of $91.(b)
Transaction and integration costs of $17,692, share-based compensation expense of $11,967, restructuring charges of $2,089 and change in fair value of contingent consideration of $1,100.(c)
Share-based compensation expense.(d)
Non-cash interest expense primarily associated with debt discount and debt issuance costs.(e)
Tax related to acquisition restructuring of $15,379 partially offset by the tax effect of non-GAAP pre-tax adjustments of $9,219.(f)
Intangible asset amortization of
'/>"/>
| SOURCE Jazz Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved |